EGFR and adenosquamous lung carcinoma: In this study, we present a case of advanced EGFR-mutated lung adenosquamous carcinoma in which the patient achieved a partial response (PR) within a short treatment duration following monotherapy with ivonescimab, a PD-1/VEGF-A bispecific monoclonal antibody, after progression on multiple lines of therapy.